Skip to main content
Fig. 10 | Journal of Neuroinflammation

Fig. 10

From: Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy

Fig. 10

Effect of PK antagonism on mechanical allodynia during repeated cycles of BTZ. Following the interruption of a classical BTZ protocol of 28 days (BTZ 0.4 mg/kg 3 times week/4 weeks) and PC1 (s.c. 150 μg/kg twice day) chronic treatment (from BTZ day 14 to 28), mice progressively recovered from BIPN. At day 84, in the presence of basal mechanical thresholds, mice that have been previously treated with the chemotherapeutic drug (first BTZ cycle) underwent a second identical treatment with BTZ (BTZ 0.4 mg/kg, 3 times week/4 weeks). At day 98, mice previously treated with PC1 started a new chronic treatment with the antagonist. All animals were monitored until the end of the second BTZ and PC1 treatment (28 days since the beginning of the second cycle corresponding to 112 days after the first BTZ injection). Data represent mean ± SD of 6 mice/group. Statistical analysis was performed by mean of two-way ANOVA followed by Bonferroni’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle/CTR; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs BTZ

Back to article page